twist siRNA (h) from Santa Cruz Biotechnology, Inc.

Product Specs
Itemtwist siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-38604
Gene Nametwist homolog 1 (Drosophila)
Quantity10 µM
Specieshuman
NCBI Full Gene Nametwist family bHLH transcription factor 1
NCBI Gene AliasesACS3, BPES2, BPES3, CRS, CRS1, CSO, SCS, SWCOS, TWIST, bHLHa38
TypesiRNA/dsRNA

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Lactate Promotes Endothelial-Mesenchymal Transition via Mediating Twist1 Lactylation in Hypoxic Pulmonary HypertensionInternational Journal of Molecular SciencesFebruary 27, 2026Xingbing Li, Fengxian Wang, Ningxin Liu, Yu Liu, Weimin Yu, Ming TangTwist in lactate-induced EndoMT, HPAECs at 70–80% confluency were transfected with Twist siRNA (100 nM, sc-38604, Santa Cruz, Dallas, TX, USA), with scrambled siRNAs serving as controls. At 24 h post-transfection,

(2) Rab31 promotes metastasis and cisplatin resistance in stomach adenocarcinoma through Twist1-mediated EMTCell death & diseaseFebruary 13, 2023Chen K, Xu J, Tong YL, Yan JF, Pan Y, Wang WJ, Zheng L, Zheng XX, Hu C, Hu X, et al.manufacturer’s instructions. The specific siRNA against Rab31 (cat. no. sc-76327), Twist1 (cat. no. sc-38604), and scramble siRNA (sc-37007) were purchased from Santa Cruz Biotechnology. The Rab31 plasmid was

(3) Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis PathwayInternational journal of molecular sciencesApril 10, 2021Bahar E, Kim JY, Kim DC, Kim HS, Yoon H.manufacturer’s instructions using Lipofectamine 2000 RNAiMAX transfection reagent (Invitrogen). Twist siRNA (#sc38604, Santa Cruz Biotechnology, Dallas, TX, USA) and control siRNA (#sc37007, Santa Cruz Biotechnology, Dallas,

(4) Retinoblastoma cell-derived Twist protein promotes regulatory T cell developmentCancer immunology, immunotherapy : CIIApril 1, 2021Zhang R, Song YN, Duo X, Guo Z, Sun Y, Zhang Z, Lu Y, Miao B, Yang PC, Nie G.

(5) Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist ExpressionInternational journal of molecular sciencesOctober 15, 2020Bahar E, Kim JY, Kim HS, Yoon H.month. 4.5. siRNA Transfection To create a knockdown of Twist, we transfected cells using Twist siRNA (#sc38604, Santa Cruz Biotechnology, Dallas, TX, USA) and control siRNA (#sc37007). The lyophilized siRNA duplex

(6) MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemnessOncogeneApril 1, 2020Li J, Pu T, Yin L, Li Q, Liao CP, Wu BJ.

(7) Inhibition of Migration, Invasion and Drug Resistance of Pancreatic Adenocarcinoma Cells - Role of Snail, Slug and Twist and Small Molecule InhibitorsOncoTargets and therapyJanuary 1, 2020Kaşıkcı E, Aydemir E, Bayrak ÖF, Şahin F.

(8) MicroRNA‑381 regulates the growth of gastric cancer cell by targeting TWIST1Molecular Medicine ReportsSeptember 6, 2019Yongling Yin, Xiaoyun Li, Zongquan Guo, Fuxiang Zhouextracted from the transfected cells 72 h after transfection. TWIST1 small interfering RNA (siRNA; cat. no. sc‑38604) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). TWIST1 siRNA transfection was

(9) N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal TransitionOxidative Medicine and Cellular LongevityJuly 1, 2019Xiuming Zhang, Jiang Chen, Shi Jiang, Shilin He, Yanfeng Bai, Linghua Zhu, Rui Ma, Xiao Liangconditions (1% O2, 94% N2, and 5% CO2). 2.2. siRNA Transfection. The NAT10 siRNA (sc62660) and Twist siRNA (sc38604) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz Biotechnology, Dallas, TX, USA). The

(10) Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathwayOncogeneJuly 1, 2019Rathore M, Girard C, Ohanna M, Tichet M, Ben Jouira R, Garcia E, Larbret F, Gesson M, Audebert S, Lacour JP, et al.siRNA duplexes were designed by Thermo Fisher Scientiﬁc. MITF (sc-35934), MYD88 (sc-35986), and TWIST1 (sc-38604) siRNAs were from Santa Cruz Biotechnology. IKKα, IKKβ, and TLR4 siRNAs were from Dharmacon (CO, USA).

(11) MiR-15a-3p suppresses the growth and metastasis of ovarian cancer cell by targeting Twist1European review for medical and pharmacological sciencesMarch 1, 2019Fan B, Chen LP, Yuan YH, Xiao HN, Lv XS, Xia ZY.

(12) MicroRNA-145 Inhibits Cell Migration and Invasion in Colorectal Cancer by Targeting TWISTOncoTargets and therapyJanuary 1, 2019Shen X, Jiang H, Chen Z, Lu B, Zhu Y, Mao J, Chai K, Chen W.

(13) FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transitionInternational journal of oncologyMay 1, 2018Zhang Y, Lu Y, Zhang C, Huang D, Wu W, Zhang Y, Shen J, Cai Y, Chen W, Yao W.

(14) TMPRSS4 Upregulates TWIST1 Expression through STAT3 Activation to Induce Prostate Cancer Cell MigrationPathology oncology research : PORApril 1, 2018Jianwei Z, Qi L, Quanquan X, Tianen W, Qingwei W.

(15) Eukaryotic translation initiation factor 5A-2 involves in doxorubicin-induced epithelial-mesenchymal transition in oral squamous cell carcinoma cellsJournal of CancerJanuary 1, 2018Fang L, Gao L, Xie L, Xiao G.

(16) The effect of TWIST silencing in metastatic chordoma cellsTurkish journal of biology = Turk biyoloji dergisiJanuary 1, 2018Aydemir E, Kaşikci E, Coşkunçelebi B, Bayrak ÖF, Şahin F.

(17) Inhibition of N-acetyltransferase 10 using remodelin attenuates doxorubicin resistance by reversing the epithelial-mesenchymal transition in breast cancerAmerican journal of translational researchJanuary 1, 2018Wu J, Zhu H, Wu J, Chen W, Guan X.

(18) Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expressionInternational journal of cancerDecember 1, 2017Wu YH, Huang YF, Chang TH, Chou CY.

(19) DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transitionOncotargetNovember 7, 2017Kang X, Li M, Zhu H, Lu X, Miao J, Du S, Xia X, Guan W.

(20) Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transportersOncotargetAugust 8, 2017Liu YR, Liang L, Zhao JM, Zhang Y, Zhang M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, et al.